OptimizeRx (NASDAQ:OPRX – Get Free Report) and Claritev (NYSE:CTEV – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
Analyst Recommendations
This is a summary of recent recommendations and price targets for OptimizeRx and Claritev, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OptimizeRx | 0 | 3 | 6 | 0 | 2.67 |
| Claritev | 1 | 2 | 6 | 0 | 2.56 |
OptimizeRx currently has a consensus price target of $11.21, indicating a potential upside of 67.38%. Claritev has a consensus price target of $44.83, indicating a potential upside of 144.59%. Given Claritev’s higher probable upside, analysts clearly believe Claritev is more favorable than OptimizeRx.
Earnings and Valuation
This table compares OptimizeRx and Claritev”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OptimizeRx | $109.43 million | 1.16 | $5.13 million | $0.25 | 26.80 |
| Claritev | $965.41 million | 0.32 | -$284.28 million | ($16.42) | -1.12 |
OptimizeRx has higher earnings, but lower revenue than Claritev. Claritev is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares OptimizeRx and Claritev’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OptimizeRx | 5.33% | 9.58% | 7.47% |
| Claritev | -27.05% | N/A | -5.74% |
Institutional and Insider Ownership
76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 87.2% of Claritev shares are held by institutional investors. 7.5% of OptimizeRx shares are held by insiders. Comparatively, 7.4% of Claritev shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
OptimizeRx has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Claritev has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Summary
OptimizeRx beats Claritev on 10 of the 13 factors compared between the two stocks.
About OptimizeRx
OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company’s services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.
About Claritev
Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.
